Health-related quality-of-life and treatment targets in myasthenia gravis

Kimiaki Utsugisawa, Shigeaki Suzuki, Yuriko Nagane, Masayuki Masuda, Hiroyuki Murai, Tomihiro Imai, Emiko Tsuda, Shingo Konno, Shunya Nakane, Yasushi Suzuki, Kazuo Fujihara, Norihiro Suzuki

研究成果: Article査読

62 被引用数 (Scopus)


Introduction: The aim of this study was to determine factors affecting health-related quality of life (HRQOL) and to propose appropriate treatment targets for patients with myasthenia gravis (MG). Methods: We evaluated 640 consecutive patients with MG seen at 11 neurological centers. Two-year follow-up data were obtained for 282 patients. Correlations between detailed clinical factors and the Japanese version of the 15-item MG-specific QOL scale score were analyzed. Results: In a cross-sectional analysis of 640 MG patients, multivariate regression revealed that disease severity, as evaluated by the MG Composite (P<0.0001), total dose of oral prednisolone during the last year (P=0.002), and Cushingoid appearance index (P=0.0004), showed significant negative effects on HRQOL, but the quantitative MG score and current prednisolone dose did not. Conclusions: Achieving minimal manifestations (MM) status or better with prednisolone ≤5 mg/day was found to exert a major positive impact on HRQOL in both the cross-sectional and 2-year follow-up patient samples and can be recommended as a treatment target.

ジャーナルMuscle and Nerve
出版ステータスPublished - 2014 10月 1

ASJC Scopus subject areas

  • 生理学
  • 臨床神経学
  • 細胞および分子神経科学
  • 生理学(医学)


「Health-related quality-of-life and treatment targets in myasthenia gravis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。